Hunter Perkins Capital Management LLC Purchases 1,215 Shares of Laboratory Co. of America Holdings (NYSE:LH)

Hunter Perkins Capital Management LLC raised its position in shares of Laboratory Co. of America Holdings (NYSE:LH) by 1.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 118,990 shares of the medical research company’s stock after buying an additional 1,215 shares during the period. Laboratory Co. of America comprises 5.7% of Hunter Perkins Capital Management LLC’s portfolio, making the stock its biggest position. Hunter Perkins Capital Management LLC owned about 0.14% of Laboratory Co. of America worth $27,287,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of LH. Private Trust Co. NA grew its holdings in Laboratory Co. of America by 3.2% during the 3rd quarter. Private Trust Co. NA now owns 1,342 shares of the medical research company’s stock worth $300,000 after acquiring an additional 41 shares during the last quarter. Empirical Finance LLC grew its stake in shares of Laboratory Co. of America by 1.7% during the third quarter. Empirical Finance LLC now owns 3,055 shares of the medical research company’s stock valued at $683,000 after purchasing an additional 50 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Laboratory Co. of America by 16.4% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 354 shares of the medical research company’s stock valued at $81,000 after purchasing an additional 50 shares in the last quarter. Concord Wealth Partners raised its position in Laboratory Co. of America by 43.3% in the 3rd quarter. Concord Wealth Partners now owns 172 shares of the medical research company’s stock worth $38,000 after purchasing an additional 52 shares during the last quarter. Finally, Rehmann Capital Advisory Group raised its position in Laboratory Co. of America by 1.9% in the 3rd quarter. Rehmann Capital Advisory Group now owns 2,844 shares of the medical research company’s stock worth $637,000 after purchasing an additional 53 shares during the last quarter. Institutional investors own 95.94% of the company’s stock.

Insider Buying and Selling at Laboratory Co. of America

In other news, Director Kerrii B. Anderson sold 1,000 shares of the business’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $235,000.00. Following the sale, the director now owns 12,722 shares of the company’s stock, valued at $2,989,670. The trade was a 7.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Adam H. Schechter sold 6,189 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $243.47, for a total transaction of $1,506,835.83. Following the completion of the transaction, the chief executive officer now directly owns 87,441 shares of the company’s stock, valued at approximately $21,289,260.27. This trade represents a 6.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 24,572 shares of company stock valued at $5,915,209 in the last 90 days. 0.85% of the stock is currently owned by company insiders.

Laboratory Co. of America Price Performance

Shares of LH opened at $246.29 on Monday. The stock has a 50 day simple moving average of $234.97 and a 200 day simple moving average of $227.17. Laboratory Co. of America Holdings has a 52-week low of $191.97 and a 52-week high of $247.99. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.30 and a current ratio of 1.44. The firm has a market capitalization of $20.60 billion, a PE ratio of 47.64, a P/E/G ratio of 1.81 and a beta of 1.06.

Laboratory Co. of America (NYSE:LH) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $3.50 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.02. Laboratory Co. of America had a net margin of 3.43% and a return on equity of 15.27%. The company had revenue of $3.28 billion during the quarter, compared to analysts’ expectations of $3.26 billion. During the same quarter in the prior year, the company earned $3.38 earnings per share. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. Sell-side analysts predict that Laboratory Co. of America Holdings will post 14.51 EPS for the current fiscal year.

Laboratory Co. of America Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.17%. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 55.71%.

Wall Street Analysts Forecast Growth

LH has been the subject of several research reports. Bank of America lifted their target price on Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Piper Sandler boosted their price objective on Laboratory Co. of America from $235.00 to $240.00 and gave the stock a “neutral” rating in a report on Monday, October 28th. Evercore ISI raised shares of Laboratory Co. of America from an “in-line” rating to an “outperform” rating and boosted their price target for the stock from $260.00 to $265.00 in a research note on Tuesday, January 7th. HSBC raised shares of Laboratory Co. of America from a “hold” rating to a “buy” rating in a research note on Wednesday, October 30th. Finally, Morgan Stanley upped their target price on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $260.54.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.